Benzinga  4 hrs ago  Comment 
Eli Lilly and Co (NYSE: LLY) came out with mixed first-quarter earnings Thursday. EPS for the company, excluding items, came at $0.50 versus $0.67 reported for the same quarter last year. Derica Rice, Eli Lilly CFO, was on CNBC recently to...
Benzinga  6 hrs ago  Comment 
Eli Lilly and Co (NYSE: LLY) on Thursday reported better than expected first quarter results. In a report issued Friday, BMO Capital Markets analysts Alex Arfaei and David Redfern reiterated an Outperform rating, updated their model and boosted...
TheStreet.com  Apr 23  Comment 
NEW YORK (TheStreet) -- Eli Lilly shares are up 0.1% to $72.39 in afternoon trading on Thursday after the biotech company reported its first quarter financial results before the opening bell today.The company easily beat analysts' earnings...
Benzinga  Apr 23  Comment 
Eli Lilly and Co (NYSE: LLY) reported better-than-expected earnings for the first quarter on Thursday. The Indianapolis, Indiana-based company posted a quarterly net profit of $529.5 million, or $0.50 per share, versus a year-ago profit of...
Benzinga  Apr 22  Comment 
Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that preclinical data on the company's growing...
FiercePharma  Apr 20  Comment 
Eli Lilly's closely watched autoimmune treatment ixekizumab met its main goals in a Phase III psoriatic arthritis trial, rolling toward an FDA application and a shot at competing in a fast-crowding space.
Jutia Group  Apr 20  Comment 
[PR Newswire] - "Bringing Cancer Discoveries to Patients" is the theme of this year's AACR meeting and one that is mirrored through Lilly's commitment to broadening its portfolio of therapies that accelerate the pace and progress of cancer care....
FiercePharma  Apr 16  Comment 
Erbitux is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb has sold it in the U.S. But Erbitux no longer fits in the sweet spot for Bristol-Myers which is hot for immuno-oncology right now and so is...
Wall Street Journal  Apr 16  Comment 
Bristol-Myers Squibb said that it agreed to transfer North America commercialization rights to its cancer drug Erbitux to Eli Lilly.
Capital Essence's Investment Blog- 錢途集團 » Page not found  Apr 13  Comment 
with the S&P fast approaching record highs following last week’s rally, our near-term work on momentum and price pattern suggested that it’s a good time to take profits rather than join the buying in the hope of a prolonged uptrend.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki